Legend Biotech Corp (LEGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.39B
Last updated: Nov 17, 2026 at 11:06 AM ET
Legend Biotech Corp (LEGN) Earnings: Report Dates and Results
Legend Biotech (LEGN) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, Legend Biotech reported EPS of $0.28. It beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
LEGN has an expected report date of Mar 8, 2027.
LEGN Earnings Call
The latest LEGN earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 24 quarters below that had an estimate, LEGN beat 9, missed 14 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $359.50M, up 32.0% from $272.33M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.28 | $0.01 | $0.01 - $0.01 | N/A | N/A | N/A | 1 | 0 up, 0 down | Nov 10, 2026 | $359.50M |
| Jun 30, 2026 | $0.09 | $0.12 | N/A | -25.00% | Miss | N/A | 1 | 0 up, 0 down | Aug 11, 2026 | $387.50M |
| Mar 31, 2026 | -$0.15 | $0.01 | N/A | N/A | N/A | N/A | 1 | 0 up, 1 down | May 12, 2026 | $305.10M |
| Dec 31, 2025 | -$0.16 | -$0.19 | -$0.19 - -$0.19 | +15.79% | Beat | -214.3% | 1 | 0 up, 0 down | Mar 10, 2026 | $306.38M |
| Sep 30, 2025 | -$0.22 | -$0.18 | N/A | -22.22% | Miss | N/A | 4 | 1 up, 0 down | Nov 12, 2025 | $272.33M |
| Jun 30, 2025 | -$0.68 | -$0.23 | -$0.24 - -$0.18 | -195.65% | Miss | N/A | 3 | 1 up, 0 down | Aug 11, 2025 | $255.06M |
| Mar 31, 2025 | -$0.54 | -$0.34 | -$0.42 - -$0.17 | -58.82% | Miss | N/A | 10 | 0 up, 0 down | May 13, 2025 | $195.05M |
| Dec 31, 2024 | $0.14 | -$0.38 | -$0.53 - -$0.15 | +137.24% | Beat | N/A | 5 | 0 up, 2 down | Mar 11, 2025 | $186.52M |
| Sep 30, 2024 | -$0.68 | -$0.60 | -$0.64 - -$0.26 | -13.33% | Miss | N/A | 7 | 1 up, 0 down | Nov 12, 2024 | $160.21M |
| Jun 30, 2024 | -$0.10 | -$0.42 | -$0.68 - -$0.13 | +76.19% | Beat | N/A | 8 | 0 up, 0 down | Aug 9, 2024 | $186.52M |
| Mar 31, 2024 | -$0.32 | -$0.32 | -$0.75 - -$0.08 | 0.00% | In line | N/A | 7 | 0 up, 0 down | May 13, 2024 | $93.99M |
| Dec 31, 2023 | -$0.80 | -$0.83 | -$1.48 - -$0.50 | +3.61% | Beat | N/A | 4 | 0 up, 1 down | Mar 11, 2024 | $79.46M |
| Sep 30, 2023 | -$0.34 | -$0.74 | -$1.19 - -$0.26 | +54.05% | Beat | N/A | 5 | 2 up, 0 down | Nov 20, 2023 | $96.01M |
| Jun 30, 2023 | -$1.14 | -$0.83 | -$1.13 - -$0.35 | -37.35% | Miss | N/A | 7 | 1 up, 0 down | Aug 15, 2023 | $73.33M |
| Mar 31, 2023 | -$0.68 | -$0.72 | N/A | +5.56% | Beat | N/A | N/A | N/A | May 18, 2023 | $36.34M |
| Dec 31, 2022 | -$0.82 | -$0.56 | -$0.94 - -$0.25 | -46.43% | Miss | N/A | 10 | 2 up, 0 down | Mar 30, 2023 | $27.63M |
| Sep 30, 2022 | -$0.89 | -$0.63 | -$0.86 - -$0.28 | -41.27% | Miss | N/A | 10 | 0 up, 0 down | Nov 3, 2022 | $27.36M |
| Jun 30, 2022 | -$0.33 | -$0.31 | -$0.61 - -$0.20 | -6.38% | Miss | N/A | 9 | 0 up, 0 down | Aug 5, 2022 | $11.97M |
| Mar 31, 2022 | -$0.49 | -$0.51 | -$0.83 - -$0.29 | +3.92% | Beat | N/A | 6 | 0 up, 1 down | Jun 1, 2022 | $41.33M |
| Dec 31, 2021 | -$0.30 | -$0.41 | -$0.65 - -$0.30 | +26.83% | Beat | N/A | 6 | 2 up, 0 down | Mar 18, 2022 | $38.99M |
| Sep 30, 2021 | -$0.86 | -$0.66 | N/A | -30.30% | Miss | N/A | 4 | N/A | Nov 16, 2021 | $17.04M |
| Jun 30, 2021 | -$0.66 | -$0.43 | -$0.43 - -$0.30 | -53.49% | Miss | N/A | 4 | N/A | Aug 23, 2021 | $20.83M |
| Mar 31, 2021 | -$0.30 | -$0.35 | -$0.45 - -$0.33 | +14.29% | Beat | N/A | 3 | N/A | May 18, 2021 | $14.30M |
| Dec 31, 2020 | -$0.44 | -$0.30 | -$0.30 - -$0.25 | -46.67% | Miss | N/A | 3 | N/A | Mar 18, 2021 | $41.20M |
| Sep 30, 2020 | -$0.50 | -$0.34 | -$0.37 - -$0.24 | -47.06% | Miss | N/A | 3 | N/A | Nov 16, 2020 | $12.46M |
| Jun 30, 2020 | -$0.51 | -$0.28 | -$0.31 - -$0.21 | -82.14% | Miss | N/A | 3 | N/A | Aug 28, 2020 | $11.60M |
| Mar 31, 2020 | -$0.51 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 8, 2020 | $12.66M |
| Dec 31, 2019 | -$0.64 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2019 | $21.13M |
| Sep 30, 2019 | -$0.28 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2019 | $17.67M |
| Jun 30, 2019 | -$0.29 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 30, 2019 | $10.09M |
| Mar 31, 2019 | -$0.12 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2019 | $10.05M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.60, after -$0.96 the year before. It was $0.07 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.60 | N/A |
| Dec 31, 2024 | -$0.96 | N/A |
| Dec 31, 2023 | -$2.96 | N/A |
| Dec 31, 2022 | -$2.53 | N/A |
| Dec 31, 2021 | -$2.12 | N/A |
| Dec 31, 2020 | -$1.96 | N/A |
| Dec 31, 2019 | -$1.01 | N/A |
| Dec 31, 2018 | -$0.03 | -139.2% |
| Dec 31, 2017 | $0.07 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,400 words across 18 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,366 | 18 | |
| 2026Q2 | Jun 30, 2026 | 6,161 | 18 | |
| 2026Q1 | Mar 31, 2026 | 5,647 | 18 | |
| 2025Q4 | Dec 31, 2025 | 7,372 | 17 | |
| 2025Q3 | Sep 30, 2025 | 7,172 | 15 | |
| 2025Q2 | Jun 30, 2025 | 7,146 | 18 | |
| 2025Q1 | Mar 31, 2025 | 8,791 | 20 | |
| 2024Q4 | Dec 31, 2024 | 7,873 | 24 |
2026Q3 Earnings Call
Opening remarks
Caroline LeCates Paul Senior Director of Investor Relations Good morning. This is Caroline Paul, Senior Director of Investor Relations at Legend Biotech. Thank you for joining us today to review our third quarter 2026 performance. Prior to this call, we issued a press release announcing our financial results, which can be found on the Legend Biotech Investor Relations website. Joining me on today's call are Ingrid Zhang, our Chief Executive Officer; Alan Bash, President of CARVYKTI; and Carlos Santos, Chief Financial Officer. Following the prepared remarks, we will open the call for Q&A. Yuhong Qiu, our Interim Head of R&D, will also join us for the Q&A session. During today's call, we will be making forward-looking statements, which are subject to risks and uncertainties that may cause our actual results to differ materially from those expressed or implied here within. These forward-looking statements are discussed in greater detail in our SEC filings, which we encourage you to read and can be found under the Investors section of our company website. In addition, adjusted net income or loss is a non-IFRS metric. This non-IFRS financial measure is in addition to and not a substitute for or superior to measures of financial performance prepared in accordance with IFRS. There are a number of limitations related to the use of these non-IFRS financial measures versus their closest IFRS equivalents. However, we believe that providing information concerning adjusted net income or loss and adjusted net income or loss per share enhances an investor's understanding of our financial performance. Our press release includes IFRS to non-IFRS reconciliations for these measures. With that, I will now turn the call over to Ingrid.
Ingrid Zhang Chief Executive Officer Thank you, Caroline, and good morning, everyone. Before reviewing our third quarter results, I'd like to share a few thoughts, as this is my first earnings call as Legend's CEO. Over the past several weeks, I have spent time with colleagues across the entire organization and engaged with physicians and other stakeholders working to bring CARVYKTI to patients around the world. What has become clear to me is the strength of what Legend has built. Legend has demonstrated its ability to bring innovative cell therapy to market at meaningful scale through strong science, manufacturing excellence, and a deep focus on patients. This is incredibly difficult to accomplish and speaks to the foundation that exists, which we can leverage for the rest of the pipeline. I've also been impressed by the quality of our people and the collaborative culture across the organization. Together, these strengths reinforce my confidence in Legend's future. I joined Legend because I believe the opportunity ahead is significant. CARVYKTI continues to expand its impact for patients with multiple myeloma.
Frequently Asked Questions About LEGN
When is Legend Biotech's next earnings date?
Legend Biotech's next earnings report is expected for Mar 8, 2027.
What EPS do analysts expect from LEGN next quarter?
The consensus EPS estimate for Legend Biotech for the quarter ending Dec 31, 2026 is $0.04 from 14 analysts, with estimates from -$0.02 to $0.13.
How often does LEGN beat earnings estimates?
Legend Biotech beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate, with an average surprise of -10.73%.
LEGN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors